• Study of acellular pertussis vaccine and its effect on whooping cough colonization in healthy adults using controlled human infection

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    The Netherlands

  • Study of alpelisib in children and adults with PIK3CA-Related Overgrowth Spectrum (PROS)

    Not recruiting

    2 1
    Investigated Drugs:
    France Germany Italy The Netherlands Norway Spain

  • Study of VRDN-001 compared to placebo to evaluate safety and effectiveness in adults with chronic thyroid eye disease

    Not recruiting

    3 1 1
    Investigated Drugs:
    France Germany Hungary Italy Poland Spain

  • Study of efavaleukin alfa safety and effectiveness in adults with moderate to severe ulcerative colitis

    Not recruiting

    2 1
    Investigated Diseases:
    Austria Belgium Bulgaria Czechia Denmark Finland +11

  • Study of rimegepant for preventing chronic migraine in adolescents aged 12 to 17 years

    Not recruiting

    3 1 1
    Investigated Diseases:
    Czechia Finland Hungary Italy Poland Slovakia +1

  • Study of TAK-279 and apremilast for adults with moderate to severe plaque psoriasis

    Not recruiting

    3 1 1
    Investigated Diseases:
    Investigated Drugs:
    Germany Italy Poland

  • Study of zasocitinib (TAK-279) and apremilast compared to placebo in adults with moderate to severe plaque psoriasis

    Not recruiting

    3 1 1
    Investigated Diseases:
    Investigated Drugs:
    Bulgaria Czechia France Germany Greece Hungary +3

  • Study of Efavaleukin Alfa to Treat Adults with Moderate to Severe Ulcerative Colitis

    Not recruiting

    2 1
    Investigated Diseases:
    Austria Belgium Bulgaria Czechia Denmark Finland +11

  • Study of bemarituzumab treatment for patients with solid tumors that have high levels of FGFR2b protein

    Not recruiting

    1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Austria Belgium Bulgaria Czechia Denmark Finland +9

  • Study of Datopotamab Deruxtecan with or without Durvalumab compared to standard treatment for patients with Stage I-III triple-negative breast cancer who have remaining cancer after initial therapy

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    Belgium Denmark France Germany Greece Italy +2

powered by